Clinical Trial Update: Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating mavrilimumab to reduce progression of acute respiratory failure in COVID-19 pneumonia with systemic hyper-inflammation has completed; r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumonia

Drugs mentioned

• Mavrilimumab (mavrilimumab)

Snippet

Sponsor: The Cleveland Clinic | Conditions: COVID 19, SARS-CoV 2 | Phase 2 | Status: COMPLETED | Results posted: 2021-05-13